Where can I buy IDXX shares?
May 11, 2022 · The IDEXX Laboratories stock price fell by -1.85% on the last day (Wednesday, 11th May 2022) from $340.18 to $333.90. and has now fallen 7 days in a row. During the day the stock fluctuated 4.31% from a day low at $332.00 to a day high of $346.32. The price has fallen in 7 of the last 10 days and is down by -25.33% for this period.
Why should you buy IDEXX stock today?
Apr 11, 2022 · finance.yahoo.com - January 26 at 8:45 PM. IDEXX Laboratories (NASDAQ:IDXX) shareholders have earned a 33% CAGR over the last five years. nasdaq.com - January 25 at 12:26 PM. Investing in IDEXX Laboratories (NASDAQ:IDXX) five years ago would have delivered you a 318% gain. finance.yahoo.com - January 25 at 12:26 PM.
How is IDEXX’s global performance trending?
At the end of October, IDEXX reported a strong quarter. Organic (non- GAAP) revenue and adjusted earnings per share increased by 12% and 21%, respectively, on a constant currency basis. EPS of $1 ...
Should I invest in zomedica or IDXX?
Oct 26, 2021 · IDXX. Idexx Laboratories (IDXX) closed at $651.96 in the latest trading session, marking a -0.09% move from the prior day. This change lagged the S&P 500's 0.18% gain on the day. Prior to today's ...
Is IDXX stock a good buy?
Can idexx split?
Is idexx overvalued?
When did Idexx stock split?
Is Amazon splitting stock in 2021?
Does IDXX stock pay dividends?
Is Amazon gonna split?
How many times has Idexx stock split?
When was Amazon's last stock split?
Is IDEXX Laboratories a buy right now?
7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently...
How has IDEXX Laboratories' stock been impacted by COVID-19?
IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organizati...
When is IDEXX Laboratories' next earnings date?
IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Tuesday, May 3rd 2022. View our earnings forecast for IDEXX...
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Wednesday, February, 2nd. The company reported $1.89 earnings per s...
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Monday, February, 21st. The company provided earnings per share (EPS) guida...
What price target have analysts set for IDXX?
7 brokerages have issued 1-year price objectives for IDEXX Laboratories' shares. Their forecasts range from $610.00 to $770.00. On average, they ex...
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the following people: Jonathan J. Mazelsky , President, Chief Executive Officer & Director John Hart...
What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?
40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com . Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories...
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT) , Medtronic (MDT) , Intuitive Surgical (ISRG) , Stryker...
What happened
Shares of IDEXX Laboratories ( NASDAQ:IDXX) fell 11.7% last month, according to data provided by S&P Global Market Intelligence.
So what
At the end of October, IDEXX reported a strong quarter. Organic (non- GAAP) revenue and adjusted earnings per share increased by 12% and 21%, respectively, on a constant currency basis. EPS of $1.24 beat analyst estimates by $0.10 per share.
Now what
It may take investors a while to reset expectations, but IDEXX should continue growing. Early 2020 guidance calls for revenue growth between 9% and 10.5% (over 2019). Adjusted earnings per share are expected to increase between 17% and 20% next year.
Is IDEXX Laboratories a buy right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock.
What stocks does MarketBeat like better than IDEXX Laboratories?
Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IDEXX Laboratories wasn't one of them.
When is IDEXX Laboratories' next earnings date?
IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for IDEXX Laboratories.
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings data on Friday, July, 30th. The company reported $2.34 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.01 by $0.33. The business had revenue of $826.14 million for the quarter, compared to the consensus estimate of $794.64 million.
How has IDEXX Laboratories' stock been impacted by Coronavirus?
IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IDXX stock has increased by 177.6% and is now trading at $681.67.#N#View which stocks have been most impacted by COVID-19.
How will IDEXX Laboratories' stock buyback program work?
IDEXX Laboratories declared that its board has approved a share repurchase plan on Wednesday, February 12th 2020, which allows the company to repurchase 5,000,000 outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases.
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories issued an update on its FY 2021 earnings guidance on Friday, August, 6th. The company provided EPS guidance of $8.200-$8.360 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.100.
The veterinary products company gained after an acquisition
Fool since 2011. I write about consumer goods, the big picture, and whatever else piques my interest. Follow me on Twitter to see my latest articles, and for commentary on hot topics in retail and the broad market. Follow @tmfbowman
What happened
Shares of Idexx Laboratories ( NASDAQ:IDXX) were moving higher last month as the veterinary products company announced an acquisition at the beginning of June. According to data from S&P Global Market Intelligence, the healthcare stock finished the month up 13%.
So what
On June 2, Idexx announced the acquisition of ezyVet, a fast-growing maker of practice information management systems (PIMS) for veterinarians.
Now what
Idexx has been a top performer throughout its history; the stock has returned more than 1,500% over the last decade. In the first quarter, organic revenue jumped 21%, earnings per share was up 73%, and it raised its guidance for the year, showing it continues to put up impressive growth numbers.